跳至主要内容
临床试验/CTRI/2024/08/072837
CTRI/2024/08/072837尚未招募3 期

A randomized double blinded placebo controlled comparative clinical study to evaluate the safety and efficacy of probiotics in the management of pre-diabetic patients.

SA Pharmachem Pvt. Ltd., India.3 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2024年8月22日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
70
试验地点
3
主要终点
1. Fasting and post prandial blood sugar levels. (Time points: Day 0,

研究概览

简要总结

The subjects who fulfilled the inclusion and exclusion criteria will be enrolled in the study. 70 participants will be randomized into two groups. Dosing will be done twice daily orally for 90 days. Subjects will be asked to visit facility for their follow up on day 30, day 60 and day 90 and any other additional visits if needed.

Primary Outcome

  1. Fasting and post prandial blood sugar levels. (Time points: Day 0, Day 30, Day 60 and Day 90)

  2. HbA1c levels (Time points: Day 0 and Day 90)

  3. Overall global status of improvement and quality of life (Time points: Day 0 and Day 90)

  4. Change in the anthropometrics and blood pressure measurements from baseline to post study (Time points: Day 0 and Day 90)

  5. Change in lipid profile from baseline to post study (Time points: Day 0 and Day 90)

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Prediabetic participants with HbA1c 5.7 – 6.4
  • Willing and able to provide written informed consent prior to performing study procedures.
  • Patients between the age of 18-65 years.
  • Males or females; females must be non-pregnant / non-lactating and practicing adequate birth control measures if not menopausal.

排除标准

  • Type 1 and type 2 diabetes mellitus
  • Concomitant gastrointestinal disorders (i.e., irritable bowel syndrome, inflammatory bowel disease and coeliac disease)
  • Recent use (within the previous 4 weeks) of antibiotics and dietary supplements (fish oil, probiotics, prebiotics, multivitamins, minerals, nutraceuticals and herbal preparations)
  • K/C/o cardiovascular or renal complications.
  • Patients who are on immunomodulatory or immunosuppressants for any other illness.
  • History of allergy to probiotics.

结局指标

主要结局

1. Fasting and post prandial blood sugar levels. (Time points: Day 0,

时间窗: Day 0, Day 30, Day 60 and Day 90

Day 30, Day 60 and Day 90)

时间窗: Day 0, Day 30, Day 60 and Day 90

2. HbA1c levels (Time points: Day 0 and Day 90)

时间窗: Day 0, Day 30, Day 60 and Day 90

3. Overall global status of improvement and quality of life (Time

时间窗: Day 0, Day 30, Day 60 and Day 90

points: Day 0 and Day 90)

时间窗: Day 0, Day 30, Day 60 and Day 90

4. Change in the anthropometrics and blood pressure measurements

时间窗: Day 0, Day 30, Day 60 and Day 90

from baseline to post study (Time points: Day 0 and Day 90)

时间窗: Day 0, Day 30, Day 60 and Day 90

5. Change in lipid profile from baseline to post study (Time points:

时间窗: Day 0, Day 30, Day 60 and Day 90

Day 0 and Day 90)

时间窗: Day 0, Day 30, Day 60 and Day 90

次要结局

  • ● Each patient will undergo a complete physical examination, blood(sugar level assessment before enrolment in the study.)

研究者

发起方
SA Pharmachem Pvt. Ltd., India.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr M Sakthi Balan MD

Ki3 Private Limited

研究点 (3)

Loading locations...

相似试验

Effect of probiotics in prediabetic patients | 临床试验